45 Background: Only in the past decade has breast cancer survivorship earned formal recognition as a research discipline. Complicating survivorship research is the overlap between aging and treatment sequelae (Pan et al., Breast Cancer Res Treat 2016). The ACS/ASCO 2015 Breast Cancer Survivorship Care Guideline and the jointly sponsored 2016 Cancer Survivorship Symposium afforded an opportunity to review the “state of the science.” Methods: All 236 citations from the Guideline and all 250 abstracts from the Symposium were reviewed independently by two authors and prospectively categorized as follows: randomized trial; non-randomized study with controls; study without controls; review; and guideline. Additional categories were generated during the review process. Results: The Guideline most commonly cited reviews (n = 88, 37%), followed by 51 (22%) non-randomized, non-controlled studies and 37 (16%) randomized trials, which mostly addressed interventions for therapy sequelae such as lymphedema. Symposium abstracts most commonly described non-randomized, non-controlled studies (n = 113, 45%). Among 13 randomized trials (5%), 3 had not completed accrual; sample sizes were 60-467. 42 (17%) abstracts were identified as pilot studies and 17 (7%) as qualitative studies. 65 (26%) exclusively addressed breast cancer. Abstracts mostly covered health-related or psychosocial sequelae of therapy; however, some addressed overall survival or active cancer therapy. Conclusions: Much of the survivorship literature remains in the exploratory stage, consisting of non-controlled, pilot and qualitative studies. To optimally address survivorship issues, increasing incorporation of cancer-free, age-matched control populations is needed. [Table: see text]